Blue Stream Laboratories, an analytical laboratory specializing in recombinant glycoprotein and complex biologics characterization services, is expanding its antibody-drug conjugates (ADC) capabilities. ADCs are a growing class of drugs that use high-targeting antibodies to deliver potent anti-cancer drugs. ADCs can target and deliver higher doses to specific tumor markers, while eliminating side effects common with chemotherapy.
 
“The ADC field is expanding and, thus, generating a lot of interest and opportunities. By increasing our ADC capabilities, Blue Stream is building on nearly a decade’s worth of experience in the characterization of recombinant protein therapeutics including dozens of projects across many biologic drug conjugates,” said Mario DiPaola, Ph.D., chief scientific officer of Blue Stream Laboratories.